EUPRAXIA PHARMACEUTICALS INC.
EPRXDrugs in Pipeline
2
Phase 3 Programs
0
Upcoming Catalysts
2
Next Catalyst
Aug 11, 2026
16dMarket Overview
Stock performance and key metrics
2 upcoming, 0 past
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
EP-104IAR 25 mg | Phase 2 | Osteoarthritis, Knee | - | - |
EP-104GI | Phase 2 | Eosinophilic Esophagitis | - | - |
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in EUPRAXIA PHARMACEUTICALS INC.'s drug pipeline?→
CatalystAlert tracks 2 drug candidates in EUPRAXIA PHARMACEUTICALS INC.'s (EPRX) pipeline across Phase 2. Its lead program is EP-104IAR 25 mg (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is EUPRAXIA PHARMACEUTICALS INC.'s next FDA catalyst?→
EUPRAXIA PHARMACEUTICALS INC.'s (EPRX) next tracked catalyst is a Earnings expected August 11, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track EPRX biotech catalysts?→
Add EPRX to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow EUPRAXIA PHARMACEUTICALS INC.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.